Interferon alpha-2A in combination therapies for the treatment of chronic hepatitis C in prior non-responders to interferon monotherapy

Salmerón, Javier; Diago, M.; Andrade, Raúl J.; Perez, R.; Solà, R.; Romero, Míriam; Mata, Manuel de la; Granados, Rafael; Torrente, V.; Aguilar, José Manuel Ruano; Planas, Ramón; Pérez-Moreno, John Carlos; Casanovas, Teresa

doi:10.1016/s0168-8278(03)80846-2

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We performed a sensitivity analysis according to pre-established criteria to assess the specific effect of double therapy and triple therapy. There was no significant effect of double therapy [97][98][99][100][101][102][103][104][105]109,111,112,116,118,119,123,127] on ETR, with a mean difference of 3.1% (95% CI: K1 to 7.3%, PZ0.1), and on SR with a mean difference of 4% (95% CI: K3.3 to 4.3%, PZ0.8). Triple therapy [106][107][108]110,[113][114][115][116][117][120][121][122][124][125][126] had a significant effect on ETR (Fig.…”

Section: Amantadine Effect On Overall Patientsmentioning

confidence: 99%

“…We excluded one study [121] which combined data from relapsers and non-responders and which included mistakes for the number of patients in the table of results. Four studies [108,112,116,117] compared more than 2 groups of patients. In those studies, only groups enabling a comparison between regimens with and without amantadine were taken into account.…”

Section: Subgroup Analysis Of Amantadine Effect In Non-respondersmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of amantadine in chronic hepatitis C: a meta-analysis

Deltenre

Henrion

Canva

et al. 2004

Journal of Hepatology

View full text Add to dashboard Cite

Section: Amantadine Effect On Overall Patientsmentioning

confidence: 99%

Section: Subgroup Analysis Of Amantadine Effect In Non-respondersmentioning

confidence: 99%

Evaluation of amantadine in chronic hepatitis C: a meta-analysis

Deltenre

Henrion

Canva

et al. 2004

Journal of Hepatology

View full text Add to dashboard Cite

“…A 48‐week course with consensus IFN has been reported to achieve SVR in 13% (9/69) of such patients [21]. Induction courses of standard IFNa in combination with ribavirin was reported to achieve relatively better SVR rates of approximately 25% [22–24], while the triple combination of IFNa, ribavirin and amantadine gave very promising SVR rates of almost 50% in one study [25] but not in others [23,26–29]. The combination of PEG‐IFNa and ribavirin has been shown to be more effective than the combination of standard IFNa and ribavirin in naïve chronic hepatitis C patients [1,2] and it is anticipated to be more effective in patients who failed to achieve SVR after a previous course of IFNa monotherapy.…”

Section: Currently Available Therapeutic Optionsmentioning

confidence: 99%

“…Antisense oligonucleotides are short [15–40] synthetic nucleotide sequences stabilized usually by the addition of phosphorothioates in order to escape degradation from cellular nucleases and improve cellular uptake, stability and hybridization [60,61]. Antisense oligonucleotides bind an RNA target forming RNA–RNA (antisense RNA) or RNA–DNA (antisense DNA) hybrids, which result in inhibition of RNA translation and/or RNA replication [60,61].…”

Section: Inhibitors Of Hcv Replicationmentioning

confidence: 99%

Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options

Papatheodoridis

2004

Journal of Viral Hepatitis

View full text Add to dashboard Cite

A significant proportion of chronic hepatitis C patients fails to achieve sustained virologic response even after treatment with the current, more potent, combination of pegylated interferon-alpha (IFNa) plus ribavirin. Such patients represent a rather heterogeneous group and may be divided initially into relapsers and nonresponders. Both the type of previous therapy and of previous response are very important factors for the indication and the type of re-treatment. The combination of pegylated IFNa and ribavirin seems to be a rational approach for patients who failed to respond to IFNa monotherapy. Pegylated IFNa-based regimens appear to induce sustained responses in 40-68% of relapsers but in only 11% of nonresponders to previous therapy with standard IFNa plus ribavirin. Thus, new therapeutic approaches are needed for the latter subgroup of patients as well as those who fail to respond to pegylated IFNa-based regimens. Such new approaches currently under evaluation include the triple combination of pegylated IFNa, ribavirin, and amantadine, alternative types of IFN, use of agents with ribavirin like activity but lesser degrees of side-effects, inhibitors of hepatitis C virus (HCV) replication, mainly inhibitors of NS3 protease or helicase, antisense oligonucleotides, and ribozymes, and several immunomodulators. Moreover, maintenance antifibrotic therapy, mostly with low doses of pegylated IFNa, are under evaluation in patients with advanced fibrosis. Thus, even in the current era of the potent pegylated IFNa-based regimens, the management of these difficult-to-treat patients represents an increasingly frequent problem and perhaps the most challenging therapeutic task in chronic hepatitis C.

show abstract

Interferon alpha-2A in combination therapies for the treatment of chronic hepatitis C in prior non-responders to interferon monotherapy

Cited by 2 publications

References 0 publications

Evaluation of amantadine in chronic hepatitis C: a meta-analysis

Evaluation of amantadine in chronic hepatitis C: a meta-analysis

Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options

Contact Info

Product

Resources

About